Application of maitake polysaccharide D component or derivative thereof in preparation of anti-schizophrenia medicine

Abstract

The invention provides application of a maitake polysaccharide D component or a derivative thereof in preparation of an anti-schizophrenia medicine, and belongs to the technical field of biological medicine. The derivative comprises a salt, an ester or a glycoside formed by the salt and the ester of the D component of the maitake polysaccharide. A mouse open field experiment and a pre-pulse inhibition experiment prove that the maitake polysaccharide D component can remarkably improve the movement activity of a schizophrenia mouse and has a remarkable anti-schizophrenia effect; the anti-schizophrenia effect of the maitake polysaccharide D component is equivalent to that of a conventional anti-schizophrenia drug clozapine, and is superior to that of a conventional anti-schizophrenia drug quetiapine.

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to application of maitake mushroom polysaccharide D component or its derivatives in the preparation of anti-schizophrenia drugs. Background Art

[0002] Schizophrenia (SZ) is a chronic, disabling mental illness that affects approximately 1% of the world's population. Its characteristics include hallucinations, delusions, speech disorders, and impaired executive function. Some patients' ability to work daily is seriously affected, which brings a serious disease burden to society. As a syndrome, the core phenotype of schizophrenia can be divided into: positive symptoms (delusions and hallucinations), negative symptoms (impaired motivation, reduced spontaneous speech, and social withdrawal), and cognitive deficits. The first onset of schizophrenia is usually in late adolescence or early adulthood (15 to 28 years old), usually preceded by a prodromal period or "at-risk mental state", and cognitive or social function impairment already exists before the onset of the disease.

[0003] At present, the drugs used to treat schizophrenia are mainly antipsychotics, such as the second-generation antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole, amisulpride, etc.). These drugs can effectively reduce the positive symptoms of schizophrenia patients, but have little effect on enhancing the functional recovery of schizophrenia patients, and have many side effects, such as causing extrapyramidal symptoms or anti-adrenergic effects.

[0004] Rethinking schizophrenia as a neurodevelopmental disorder and refocusing the treatment of schizophrenia on early detection and early intervention may bring new hope for reducing the disease conversion rate and improving and maintaining patient function. However, there is currently no preventive drug for people in the early stages of schizophrenia.

[0005] Grifola frondosa (Dick. Fr.) SF Gray, also known as Maitake, is a large edible and medicinal fungus with extremely high medical and health care functions, such as enhancing the immune system, lowering blood sugar, improving spleen, liver cirrhosis, hypertension, stomach and nerve function. Maitake polysaccharide D component is a proteoglycan extracted from Maitake, which has the effects of improving human immunity, controlling tumor cell growth, preventing tumor metastasis and recurrence, and reducing the side effects of chemotherapy. Subacute toxicity experiments have shown that Maitake polysaccharide D component has no significant effect on the bone marrow, liver, kidney and other functions of rats. However, there is no report on the use of Maitake polysaccharide D component as an active ingredient to prevent or treat schizophrenia. Summary of the invention

[0006] The purpose of the present invention is to provide a use of maitake mushroom polysaccharide D component or its derivatives in the preparation of anti-schizophrenia drugs, so as to provide new drugs for the prevention and treatment of schizophrenia.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] The present invention provides application of maitake mushroom polysaccharide D component or its derivatives in preparing anti-schizophrenia drugs.

[0009] Preferably, the derivative includes a salt, an ester or a glycoside thereof formed with sugar of the maitake mushroom polysaccharide D component.

[0010] Preferably, the salt of the maitake mushroom polysaccharide D component includes hydrochloride, sulfate and phosphate.

[0011] Preferably, the anti-schizophrenia drug is a drug for preventing or treating schizophrenia.

[0012] Preferably, the medicine also contains a drug ingredient that has a positive effect on treating schizophrenia.

[0013] Preferably, the drug ingredients having a positive effect on the treatment of schizophrenia include any one or more of risperidone, olanzapine, quetiapine, aripiprazole, amisulpride and clozapine.

[0014] Preferably, the medicine further contains pharmaceutically acceptable excipients.

[0015] Preferably, the auxiliary materials include diluents, absorbents, wetting agents, binders, disintegrants, disintegration inhibitors, absorption enhancers and lubricants.

[0016] Preferably, the dosage form of the drug includes liquid dosage form and solid dosage form, the liquid dosage form includes oral solution, suspension, injection solution and infusion solution, and the solid dosage form includes powder, granule, tablet, capsule and pill.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The present invention confirms through mouse open field test and prepulse inhibition test that maitake polysaccharide D component can significantly improve the motor activity of schizophrenia mice and has a significant anti-schizophrenia effect; the anti-schizophrenia effect of maitake polysaccharide D component is equivalent to the conventional anti-schizophrenia drug clozapine, and is superior to the conventional anti-schizophrenia drug quetiapine. Therefore, maitake polysaccharide D component or its derivatives can be used as an effective ingredient for preparing anti-schizophrenia drugs, with the advantages of significant anti-schizophrenia effect, good safety, and few side effects, and is expected to become a fast, efficient, and new mechanism anti-schizophrenia new drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0020] Figure 1 is the structural formula of the D component of maitake mushroom polysaccharide;

[0021] Figure 2 is the movement distance of mice in different treatment groups in the open field test in Experimental Example 1;

[0022] Figure 3 is the startle amplitude of mice in each treatment group at the prepulse stimulus intensity 6 dB higher than the background sound in Experimental Example 2;

[0023] Figure 4 This is the startle amplitude of mice in each treatment group under the prepulse stimulation intensity of 15 dB higher than the background sound in Experimental Example 2. DETAILED DESCRIPTION

[0024] The present invention provides application of maitake mushroom polysaccharide D component or its derivatives in preparing anti-schizophrenia drugs.

[0025] In the present invention, the derivative includes a salt, an ester or a glycoside formed by a maitake mushroom polysaccharide D component and sugar.

[0026] In the present invention, the salt of the maitake mushroom polysaccharide D component includes hydrochloride, sulfate and phosphate.

[0027] In the present invention, the anti-schizophrenia drug is a drug for preventing or treating schizophrenia.

[0028] In the present invention, the medicine also contains a drug component that has a positive effect on treating schizophrenia.

[0029] In the present invention, the drug ingredients having a positive effect on the treatment of schizophrenia include any one or more of risperidone, olanzapine, quetiapine, aripiprazole, amisulpride and clozapine.

[0030] In the present invention, the medicine further contains pharmaceutically acceptable excipients.

[0031] In the present invention, the auxiliary materials include diluents, absorbents, wetting agents, binders, disintegrants, disintegration inhibitors, absorption promoters and lubricants.

[0032] In the present invention, the dosage form of the drug includes liquid dosage form and solid dosage form, the liquid dosage form includes oral solution, suspension, injection and drip solution, and the solid dosage form includes powder, granule, tablet, capsule and pill.

[0033] In the present invention, the drug can be made into a common preparation, or a sustained-release preparation, a controlled-release preparation, a targeted preparation and various microparticle drug delivery systems.

[0034] In the present invention, the administration route can be injection, which includes intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection and acupoint injection.

[0035] In the present invention, the route of administration can be enteral or parenteral, such as oral, intramuscular, subcutaneous, nasal, oral mucosa, skin, peritoneum or rectum.

[0036] In the present invention, in order to prepare the unit dosage form into tablets, various carriers known in the art can be widely used. The diluent and absorbent in the carrier may be starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, white clay, microcrystalline cellulose, aluminum silicate, etc.; the wetting agent and adhesive may be water, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinyl pyrrolidone, etc.; the disintegrant may be dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate, citric acid, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose, etc.; the disintegration inhibitor may be sucrose, tristearin, cocoa butter, hydrogenated oil, etc.; the absorption promoter may be quaternary ammonium salt, sodium dodecyl sulfate, etc.; the lubricant may be talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, etc. The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.

[0037] In the present invention, in order to make the dosing unit into a pill, various carriers known in the art can be widely used. The diluent and absorbent in the carrier can be glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinyl pyrrolidone, Gelucire, kaolin, talc, etc.; the binder can be gum arabic, tragacanth gum, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc.; the disintegrant can be agar powder, dry starch, alginate, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose, etc.

[0038] In the present invention, in order to prepare the administration unit into a suppository, various carriers known in the art can be widely used, such as polyethylene glycol, lecithin, cocoa butter, higher alcohols, enzymes of higher alcohols, gelatin, semi-synthetic glycerol enzymes, and the like.

[0039] In the present invention, in order to prepare the dosing unit into a capsule, the active ingredient is mixed with the above-mentioned various carriers, and the resulting mixture is placed in a hard gelatin capsule or a soft capsule. The active ingredient can also be prepared into a microcapsule, suspended in an aqueous medium to form a suspension, or loaded into a hard capsule or prepared as an injection for use.

[0040] In the present invention, the composition of the present invention can be made into an injection preparation, such as a solution, a suspension solution, an emulsion, or a freeze-dried powder injection. This preparation can be aqueous or non-aqueous, and can contain one and / or more pharmacodynamically acceptable carriers, diluents, adhesives, lubricants, preservatives, surfactants, or dispersants. For example, the diluent can be selected from water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol, polyoxyethylene sorbitol fatty acid enzyme, etc. In addition, in order to prepare an isotonic injection, an appropriate amount of sodium chloride, glucose, or glycerol can be added to the injection preparation. In addition, conventional cosolvents, buffers, pH regulators, etc. can also be added. These excipients are commonly used in the art.

[0041] Furthermore, if necessary, colorants, preservatives, perfumes, flavoring agents, sweeteners or other materials may be added to the pharmaceutical preparations.

[0042] In the present invention, the application dosage of the drug is 0.001 to 30 mg of maitake mushroom polysaccharide D component or its derivatives per kilogram of body weight.

[0043] The dosage of the pharmaceutical composition of the present invention depends on many factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight, personality and individual response of the patient or animal, the route of administration, the number of administrations, etc., so the therapeutic dose of the present invention can vary widely. Generally speaking, the dosage of the drug of the present invention can be appropriately adjusted according to the actual amount of effective drug contained in the final preparation of the pharmaceutical composition of the present invention to achieve the requirement of its therapeutically effective amount.

[0044] The anti-schizophrenia drug provided by the present invention includes two stages: prevention and treatment. In the prevention stage, the dosage of the anti-schizophrenia drug of the present invention is: 0.001-3 mg of maitake polysaccharide D component and its derivatives per kilogram of body weight per day; in the treatment stage, the dosage of the anti-schizophrenia drug of the present invention is: 0.01-30 mg of maitake polysaccharide D component and its derivatives per kilogram of body weight per day. The anti-schizophrenia drug is administered orally, by nasal spray, drip or injection; the subject of administration is a mammal, and the mammal includes a human.

[0045] The technical solutions provided by the present invention are described in detail below with reference to the examples, but they should not be construed as limiting the scope of protection of the present invention. The structural formula of the maitake polysaccharide D component (Proteo-β-glucan from Maitake) used in the following examples is as follows: Figure 1 The preparation method of Maitake polysaccharide D component was referred to "Bao H, Ran P, Zhu M, et al. The Prefrontal Dectin-1 / AMPA Receptor Signaling Pathway Mediates The Robust and Prolonged Antidepressant Effect of Proteo-β-Glucan from Maitake [J]. Scientific Reports, 2016, 6 (1).", and the product was purchased from Maitake mushrooms (UPC code: 791014107211) and then extracted.

[0046] Example 1

[0047] Take 150g of maitake polysaccharide D component, 300g of lactose as a filler, 2.25g of magnesium stearate as a lubricant, and 4.5g of silicon dioxide as an anti-caking agent, sieve and mix, and put into capsules to prepare 1000 capsules of maitake polysaccharide D component. The content of maitake polysaccharide D component is obtained by quantitative analysis, which is used as the basis for the dosage.

[0048] Example 2

[0049] 150 g of maitake polysaccharide D component was diluted with water and flavored with stevioside to prepare a 10% liquid medicine to obtain an oral solution of maitake polysaccharide D component. The content of maitake polysaccharide D component was obtained by quantitative analysis and used as the basis for the dosage.

[0050] Example 3

[0051] Take 100g of maitake polysaccharide D component, dissolve it in 500mL of anhydrous ethanol, add 3% dilute hydrochloric acid solution to pH=6, let it stand until crystals precipitate, then filter, dry the solid part to obtain maitake polysaccharide D component hydrochloride; add injection water for fine filtration according to routine procedures, fill and sterilize to make an injection solution.

[0052] Example 4

[0053] Take 200g of maitake polysaccharide component D, dissolve it in 1000mL of anhydrous ethanol, add 5% ethanolic sulfuric acid solution to pH = 6, let it stand until crystals precipitate, then filter, dry the solid part, and obtain maitake polysaccharide component D sulfate; dissolve the obtained maitake polysaccharide component D sulfate in sterile water for injection at a mass volume ratio of 1g:500mL, add 5% glucose as an excipient, stir and mix, filter through a sterile suction funnel, sterile fine filter, and divide into 2 ampoules. After low-temperature freeze-drying, sterilize and seal to obtain a powder injection.

[0054] Example 5

[0055] The maitake mushroom polysaccharide D component is mixed with an excipient (starch) at a weight ratio of 9:1 to obtain a powder.

[0056] Example 6

[0057] The maitake mushroom polysaccharide D component is mixed with an excipient (starch) at a weight ratio of 1:8, granulated and tableted to obtain tablets.

[0058] Example 7

[0059] Dissolve 50 g of maitake polysaccharide D component in 300 mL of anhydrous ethanol, add 3% ethanolic phosphoric acid solution until pH = 6, let stand until crystals precipitate, then filter, dry the solid part to obtain maitake polysaccharide D component phosphate; prepare oral liquid according to conventional oral liquid preparation method.

[0060] Example 8

[0061] The maitake mushroom polysaccharide D component is mixed with auxiliary materials in a weight ratio of 5:1 to prepare capsules (auxiliary materials: lactose 10% + talcum powder 1% + starch 2%) or granules (auxiliary materials: water 5% + starch 5% + lactose 10% + talcum powder 1%) or instant powder (auxiliary materials: lactose 10% + citric acid 1% + magnesium oxide 0.1% + peppermint oil 0.1%).

[0062] Example 9

[0063] The maitake mushroom polysaccharide D component is mixed with auxiliary materials in a weight ratio of 3:1 to prepare capsules (auxiliary materials: lactose 10% + talcum powder 1% + starch 2%) or granules (auxiliary materials: water 5% + starch 5% + lactose 10% + talcum powder 1%) or instant powder (auxiliary materials: lactose 10% + citric acid 1% + magnesium oxide 0.1% + peppermint oil 0.1%).

[0064] Example 10

[0065] 46.6 g of maitake mushroom polysaccharide D component, 600 g of starch, 200 g of lactose, 3 g of menthol and 152 g of sodium carboxymethyl starch were mixed to prepare lozenges as a functional food.

[0066] Experimental Example 1 Effect of Maitake Polysaccharide D Component on the Open Field Test of Animal Schizophrenia Model

[0067] Experimental animals: 6-week-old C57BL / 6 male mice were purchased (provided by Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Beijing) 2020-0004). The mice were housed in separate cages, with a light / dark cycle of 12h / 12h, a temperature of 20-22°C, and free access to food and water (food was provided by Beijing Huilinzegu Biotechnology Co., Ltd.).

[0068] Experimental drugs: Proteo-β-glucan from Maitake (PGM) was purchased from Maitake mushrooms (UPC code: 791014107211) and then polysaccharide extraction was performed. The specific method was: one volume of the product was mixed with three volumes of alcohol (95%), and the supernatant was removed after standing at room temperature for one hour and centrifuged (12000 rpm) for 60 minutes. After drying at room temperature, the D component of maitake polysaccharide was obtained. Cuprizon (CPZ) was a product of Sigma, with the product number C9012 and the CAS number 370-81-0. Clozapine (CLZ) was a product of TCI, with the product number C2547 and the CSA number 5786-21-0.

[0069] Animal grouping: After one week of adaptive feeding, male C57B / 6 mice were divided into 5 groups, with 10 mice in each group, namely normal control group (CON), model group (CPZ), low-dose treatment group of maitake polysaccharide D component (PGM-L), high-dose treatment group of maitake polysaccharide D component (PGM-H) and positive control group (CLZ).

[0070] Animal administration: Except for the normal control group, which was fed with normal feed (the feed was purchased from Suzhou Shuangshi Company), the other groups were fed with feed containing 0.2% Cuprizon (CPZ) for 28 days to establish an animal model of schizophrenia. After the modeling, the normal control group and the modeling group were injected with saline containing 2% DMSO, the low-dose treatment group of maitake polysaccharide D component (PGM-L) was injected with saline solution containing 5 mg / kg maitake polysaccharide D component and 2% DMSO, the high-dose treatment group of maitake polysaccharide D component (PGM-H) was injected with saline solution containing 10 mg / kg maitake polysaccharide D component and 2% DMSO, and the positive control group was injected with saline solution containing 10 mg / kg clozapine and 2% DMSO; each group was intraperitoneally injected with 10 mL / kg body weight at 10 am every day, and an open field test was performed 24 hours after administration on the 14th day. The open field time was 30 minutes, and the Any-maze software system was used for video recording and analysis. All experimental results were expressed as mean ± SEM and analyzed by one-way analysis of variance (ANOVA). When the samples did not meet the normal distribution, the Kruskal-Wallis test was used, followed by Dunnett's multiple comparison test.

[0071] The analysis results are as follows Figure 2 As shown (** indicates p < 0.01, *** indicates p < 0.001), it can be seen that after C57B / 6 male mice were treated with different doses of maitake polysaccharide D component, the high-dose group (10 mg / kg) showed a significant anti-schizophrenia effect in the mouse open field test.

[0072] Experimental Example 2 Effect of Maitake Polysaccharide D Component on Prepulse Inhibition (PPI) Experiment in Animal Schizophrenia Model

[0073] Experimental animals: 6-week-old C57BL / 6 male mice were purchased (provided by Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Beijing) 2020-0004). The mice were housed in separate cages, with a light / dark cycle of 12h / 12h, a temperature of 20-22°C, and free access to food and water (food was provided by Beijing Huilinzegu Biotechnology Co., Ltd.).

[0074] Experimental drugs: Proteo-β-glucan from Maitake (PGM) was purchased from Maitake mushrooms (UPC code: 791014107211) and then polysaccharide extraction was performed. The specific method was: one volume of the product was mixed with three volumes of alcohol (95%), and the supernatant was removed after standing at room temperature for one hour and centrifuged (12000 rpm) for 60 minutes. After drying at room temperature, the D component of maitake polysaccharide was obtained. Cuprizon (CPZ) was a product of Sigma, with the product number C9012 and the CAS number 370-81-0. Quetiapine hemifumarate (QTP) was a product of MCE, with the product number HY-B0031 and the CSA number 111974-72-2.

[0075] Animal grouping: After one week of adaptive feeding, male C57B / 6 mice were divided into 5 groups, with 8 mice in each group, namely the normal control group (CON), the model group (CPZ), the low-dose treatment group of maitake polysaccharide D component (PGM-L), the high-dose treatment group of maitake polysaccharide D component (PGM-H) and the positive control group (QTP).

[0076] Animal administration: Except for the normal control group, which was fed with normal feed (the feed was purchased from Suzhou Shuangshi Company), the other groups were fed with feed containing 0.2% Cuprizon (CPZ) for 28 days to establish an animal model of schizophrenia. After the modeling, the normal control group and the modeling group were injected with saline containing 2% DMSO, the low-dose treatment group of maitake polysaccharide D component (PGM-L) was injected with saline containing 5 mg / kg maitake polysaccharide D component and 2% DMSO, the high-dose treatment group of maitake polysaccharide D component (PGM-H) was injected with saline containing 10 mg / kg maitake polysaccharide D component and 2% DMSO, and the positive control group was injected with saline containing 10 mg / kg quetiapine and 2% DMSO; each group was intraperitoneally injected at a dose of 10 mL / kg body weight at 10 am every day, and the PPI experiment was performed 24 hours after administration on the 14th day.

[0077] The test equipment used in the PPI experiment was purchased from MEDAssociates, and consists of main modules such as a soundproof box, a loudspeaker, a mouse cage, a gravity sensor (PHM-255A and PHM-250B), and the Startle Reflex 5 software system. Before the formal test, the mice were placed in the fixed cage for 25 minutes every day for three days of adaptation. Parameter setting: background noise (white noise, 60dB) was turned on throughout the entire experimental stage, and the test was divided into three stages: adaptation period, Block I and Block II. During the adaptation period, there was only 60dB background noise, which lasted for 5 minutes. Block I included 10 trails, 10 startle stimuli (110dB), no prepulse stimulus, and 110dB white noise was used as a startle. The stimulus duration was 20ms, and the trial interval varied from 15 to 30s. Block II included five stimulus types: no stimulus (only 60dB background sound), 110dB startle stimulus (same as above), 66dB prepulse stimulus + 110dB startle stimulus, 75dB prepulse stimulus + 110dB startle stimulus, 75dB prepulse stimulus (no startle). The two prepulse stimulus intensities were 6dB and 15dB higher than the background sound, respectively. The stimulus duration was 10ms, and the prepulse / startle stimulus delay was set to 100ms. Each of the above stimulus types appeared 10 times in a pseudo-random manner, for a total of 50 trials, with an interval of 20s between each trial.

[0078] The experimental index was reflected by the startle amplitude of mice, and the PPI (%) was calculated as: [1-(prepulse + startle amplitude) / startle amplitude] × 100%. All experimental results were expressed as mean ± SEM, and one-way analysis of variance ANOVA was used for the test. When the samples did not meet the normal distribution, the Kruskal-Wallis test was used, and the Dunnett multiple comparison test was performed afterwards.

[0079] At a prepulse stimulus intensity 6 dB higher than the background sound, the startle amplitude of mice in each treatment group was as follows Figure 3 As shown (* indicates p < 0.05); at a prepulse stimulus intensity 15 dB higher than the background sound, the startle amplitude of mice in each treatment group is as follows Figure 4 As shown (* indicates p < 0.05, ** indicates p < 0.01). Figure 3 It can be seen that at a prepulse stimulation intensity 6 dB higher than the background sound, the low-dose and high-dose groups of maitake polysaccharide D component can improve the sensorimotor gating defects of the schizophrenia mouse model, and the low-dose group of maitake polysaccharide D component has a comparable therapeutic effect to the traditional antipsychotic drug quetiapine; Figure 4It can be seen that at a prepulse stimulation intensity of 15dB higher than the background sound, both the low-dose group and the high-dose group of maitake polysaccharide D component can effectively improve the sensorimotor gating defect of the schizophrenia mouse model, and the low-dose group showed a higher efficacy than the traditional antipsychotic drug quetiapine. It can be seen that compared with the traditional antipsychotic drug quetiapine, the anti-schizophrenia effect of maitake polysaccharide D component is stronger.

[0080] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of maitake mushroom polysaccharide D component or its derivatives in the preparation of anti-schizophrenia drugs.

2. The use according to claim 1, characterized in that The derivatives include salts, esters or glycosides formed by the maitake mushroom polysaccharide D component and sugars.

3. The use according to claim 1, characterized in that The salts of the maitake mushroom polysaccharide D component include hydrochloride, sulfate and phosphate.

4. The use according to claim 1, characterized in that The anti-schizophrenia drug is a drug for preventing or treating schizophrenia.

5. The use according to claim 1, characterized in that The medicine also contains a medicinal ingredient which has a positive effect on treating schizophrenia.

6. The use according to claim 5, characterized in that The drug ingredients having a positive effect on treating schizophrenia include any one or more of risperidone, olanzapine, quetiapine, aripiprazole, amisulpride and clozapine.

7. The use according to claim 1, characterized in that The medicine also contains pharmaceutically acceptable excipients.

8. The use according to claim 7, characterized in that The auxiliary materials include diluents, absorbents, wetting agents, binders, disintegrants, disintegration inhibitors, absorption promoters and lubricants.

9. The use according to any one of claims 1 to 8, characterized in that: The dosage form of the drug includes liquid dosage form and solid dosage form. The liquid dosage form includes oral solution, suspension, injection solution and drip solution, and the solid dosage form includes powder, granule, tablet, capsule and pill.

Images